0000000000965471

AUTHOR

José A. Amado

showing 3 related works from this author

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardi…

2014

Data on the long-term metabolic side-effects associated with antipsychotics are scarce. Prospective longitudinal studies in medication-naive patients with a first episode of psychosis are a valuable source of information as they provide an assessment prior to the antipsychotic exposure and minimize the effect of potential confounding factors. The aim of this study was to assess the course of weight gain and the incidence of metabolic abnormalities during the first 3 yr of antipsychotic treatment. Data were collected from a cohort of 170 first-episode psychosis patients. They were randomly assigned to haloperidol (32%); olanzapine (32%) and risperidone (36%). The dose used was flexible. The …

OlanzapineAdultMaleMedication-naivemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentWeight GainBenzodiazepinesYoung AdultMetabolic DiseasesRisk FactorsMetabolic side effectsInternal medicinemedicineHumansAntipsychoticsPharmacology (medical)Prospective StudiesAntipsychoticPsychiatryProspective cohort studyPharmacologyFirst episodeRisperidoneMiddle AgedRisperidoneFirst-episode psychosisCardiovascular riskCritical periodPsychiatry and Mental healthTolerabilityPsychotic DisordersOlanzapineCohortHaloperidolmedicine.symptomPsychologyWeight gainmedicine.drugAntipsychotic Agents
researchProduct

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.

2013

This randomized open-label study compared the incidence of metabolic side effects of aripiprazole, ziprasidone and quetiapine in a population of medication-naive first-episode psychosis patients. A total of 202 subjects were enrolled. Body weight, body mass index, leptin, fasting lipids and fasting glycaemic parameters were measured at baseline and at 3 months follow-up. A hundred and sixty-six patients completed the follow-up and were included in the analyses. A high proportion of patients experienced a significant weight increase (>7% of their baseline weight): 23% ziprasidone (n=12), 32% with quetiapine (n=16) and 45% with aripiprazole (n=31). Patients treated with aripiprazole gained si…

AdultMalemedicine.medical_specialtyPsychosisDibenzothiazepinesPopulationAripiprazoleQuinolonesWeight GainGastroenterologyPiperazinesQuetiapine FumarateSex FactorsInternal medicinemedicineHumansZiprasidoneeducationPsychiatryBiological Psychiatryeducation.field_of_studybusiness.industryLeptinmedicine.diseaseProlactinPsychiatry and Mental healthThiazolesCholesterolPsychotic DisordersQuetiapineAripiprazoleFemalemedicine.symptombusinessWeight gainBody mass indexmedicine.drugAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct

Association of ACACB polymorphisms with obesity and diabetes

2011

El pdf del artículo es la versión pre-print.-- et al.

medicine.medical_specialtyLinkage disequilibriumEndocrinology Diabetes and MetabolismPopulationSingle-nucleotide polymorphismType 2 diabetesBiologyBiochemistryPolymorphism Single NucleotideLinkage DisequilibriumCohort StudiesEndocrinologyInternal medicineGeneticsmedicineHumansObesityAlleleeducationMolecular BiologyAllelesGenetic Association StudiesAgedGeneticsACACBAged 80 and overeducation.field_of_studyHaplotypeAcetyl-CoA carboxylaseType 2 diabetesMiddle Agedmedicine.diseasePostmenopauseEndocrinologyDiabetes Mellitus Type 2HaplotypesACACBCase-Control StudiesFemalePolymorphismsAcetyl-CoA Carboxylase
researchProduct